Development and Evaluation of a Novel Software Program, SAKURA-TDM, for Area Under the Concentration-Time Curve–Guided Vancomycin Dosing: A Short Communication

Supplemental Digital Content is Available in the Text. Background: The area under the concentration-time curve (AUC)–guided dosing of vancomycin has been introduced in Japan; however, the optimal dosing method remains controversial. Here, a novel software program was developed for AUC-guided vancomycin dosing and to estimate the theoretical threshold of the steady-state AUC24 that could reduce the risk of renal injury. Methods: A single-center, retrospective, observational study was conducted to develop a novel software program (SAKURA-TDM ver.1.0) for AUC-guided dosing. The estimation accuracy of pharmacokinetic parameters determined using SAKURA-TDM was compared with that of clinically available software programs and assessed with Bland–Altman analysis. In addition, theoretical cutoff points of the steady-state AUC24 and the predicted trough values were estimated using Youden J statistic approach. Results: The estimation accuracy of pharmacokinetic parameters and AUC determined using SAKURA-TDM was comparable to that of other TDM software programs. Of note, despite a good relationship between the predicted AUC24 and trough values, the correlation between the predicted AUC24 and measured trough values was not strong. The cutoff values of the steady-state AUC24 and the predicted trough value for reducing the probability of a measured trough value of >20 mcg/mL were 513.1 mg·h/L and 15.6 mcg/mL, respectively. Conclusions: We demonstrated the equivalence of the estimated PK parameters between SAKURA-TDM and other TDM software programs available in Japan. Considering the threshold of both trough values and the steady-state AUC and monitoring of the AUC in a non–steady state, it would be possible to reduce the risk of vancomycin-associated renal injury.

[1]  Y. Takekuma,et al.  Using Japanese big data to investigate novel factors and their high‐risk combinations that affect vancomycin‐induced nephrotoxicity , 2022, British journal of clinical pharmacology.

[2]  H. Ikeuchi,et al.  Validation of Vancomycin Area under the Concentration—Time Curve Estimation by the Bayesian Approach Using One-Point Samples for Predicting Clinical Outcomes in Patients with Methicillin-Resistant Staphylococcus aureus Infections , 2022, Antibiotics.

[3]  M. Holubar Faculty Opinions recommendation of The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[4]  Kazuaki Matsumoto,et al.  Performance of Area under the Concentration-Time Curve Estimations of Vancomycin with Limited Sampling by a Newly Developed Web Application , 2021, Pharmaceutical Research.

[5]  Kazuaki Matsumoto,et al.  The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing , 2021, BMC Infectious Diseases.

[6]  K. Rodvold 60 Plus Years Later and We Are Still Trying to Learn How to Dose Vancomycin. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Lee P. Skrupky,et al.  Examining the relationship between vancomycin area under the concentration time curve and serum trough levels in adults with presumed or documented staphylococcal infections. , 2019, Therapeutic drug monitoring.

[8]  S. Tongsai,et al.  The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis , 2016, BMC Research Notes.

[9]  J. Prybylski Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta‐analysis of Observational Studies , 2015, Pharmacotherapy.

[10]  Roger W. Jelliffe,et al.  Are Vancomycin Trough Concentrations Adequate for Optimal Dosing? , 2013, Antimicrobial Agents and Chemotherapy.

[11]  Y. Nishi,et al.  Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[12]  Marlea G. Wellein,et al.  Relationship between Vancomycin Trough Concentrations and Nephrotoxicity: a Prospective Multicenter Trial , 2011, Antimicrobial Agents and Chemotherapy.

[13]  N. Shime,et al.  The importance of a judicious and early empiric choice of antimicrobial for methicillin-resistant Staphylococcus aureus bacteraemia , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[14]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  T. Iga,et al.  Population pharmacokinetics of vancomycin in Japanese adult patients. , 1998, Therapeutic drug monitoring.

[16]  S. Higuchi,et al.  PEDA: a microcomputer program for parameter estimation and dosage adjustment in clinical practice. , 1987, Journal of pharmacobio-dynamics.

[17]  K Yamaoka,et al.  A nonlinear multiple regression program, MULTI2 (BAYES), based on Bayesian algorithm for microcomputers. , 1985, Journal of pharmacobio-dynamics.

[18]  Douglas G. Altman,et al.  Measurement in Medicine: The Analysis of Method Comparison Studies , 1983 .

[19]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.

[20]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[21]  John A. Nelder,et al.  A Simplex Method for Function Minimization , 1965, Comput. J..

[22]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.